Area of research
Endocrinology, Diabetes and Metabolism · Pathology and Forensic Medicine
Research interest
Research interests include Ophthalmology and Eye Disorders, Thyroid Disorders and Treatments, Diabetes and associated disorders, and Pituitary Gland Disorders and Treatments.
Secukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.
Type 1 Diabetes and Other Autoimmune Diseases-Epidemiology, Pathophysiology and Screening.
Bibliometrics in thyroid eye disease.
Targeted immunotherapies for Graves’ thyroidal & orbital diseases
Unravelling the pathogenic mechanisms in Graves’ orbitopathy
Inflammatory and tolerogenic dendritic cells and T lymphocytes in Graves' thyroidal and orbital disease
Hypothyroidism: playing the cardiometabolic risk concerto
Stress and Thyroid Function—From Bench to Bedside
High-Throughput Proteomics and Immunohistochemistry of Orbital Connective Tissue in Graves' Orbitopathy
Process to radioactive iodine treatment for Graves’ hyperthyroidism: condemned or absolved?
Analysis of non-cholesterol sterols and fatty acids in patients with graves’ orbitopathy: insights into lipid metabolism in relation to the clinical phenotype of disease
Unravelling the pathogenic mechanisms in Graves' orbitopathy.
Stress and Thyroid Function-From Bench to Bedside.
US-based, Prospective, Blinded Study of Thyrotropin Receptor Antibody in Autoimmune Thyroid Disease.
High-Throughput Proteomics and Immunohistochemistry of Orbital Connective Tissue in Graves' Orbitopathy.
Teprotumumab Improves Quality of Life in Thyroid Eye Disease: Meta-analysis and Matching-adjusted Indirect Comparison.
Analytical validation of a novel bioassay for thyroid-stimulating immunoglobulin
Type 1 Diabetes and Other Autoimmune Diseases—Epidemiology, Pathophysiology and Screening
Graves' disease in ectopic thyroid tissue: a scoping review and a case study.
Comparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves' orbitopathy.
Redox mechanisms in autoimmune thyroid eye disease
Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials
Linsitinib inhibits proliferation and induces apoptosis of both IGF-1R and TSH-R expressing cells
A novel bioassay for thyroid-blocking immunoglobulins
Androgens contribute to sex bias of autoimmunity in mice by T cell-intrinsic regulation of Ptpn22 phosphatase expression
Safety and tolerability of anti-FcRn monoclonal antibody in thyroid autoimmunity
Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease
Thyroid Eye Disease: Epidemiology, Natural History, and Risk Factors
Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease.
Presentation of Graves’ orbitopathy within European Group On Graves’ Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III)